

A&I

ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

Offizielles Organ: Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e. V. (DGAI)
Berufsverband Deutscher Anästhesisten e. V. (BDA)

Organ: Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e. V. (DIVI)



Amyotrophic lateral sclerosis

Donohue syndrome

orphan**a**nesthesia

a project of the German Society
of Anaesthesiology and Intensive Care Medicine

SUPPLEMENT NR. 1 | 2023

OrphanAnesthesia –

ein krankheitsübergreifendes Projekt des Wissenschaftlichen Arbeitskreises Kinderanästhesie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V.

Ziel des Projektes ist die Veröffentlichung von Handlungsempfehlungen zur anästhesiologischen Betreuung von Patienten mit seltenen Erkrankungen. Damit will Orphan Anesthesia einen wichtigen Beitrag zur Erhöhung der Patientensicherheit leisten.

Patienten mit seltenen Erkrankungen benötigen für verschiedene diagnostische oder therapeutische Prozeduren eine anästhesiologische Betreuung, die mit einem erhöhten Risiko für anästhesieassoziierte Komplikationen einhergehen. Weil diese Erkrankungen selten auftreten, können Anästhesisten damit keine Erfahrungen gesammelt haben, so dass für die Planung der Narkose die Einholung weiterer Information unerlässlich ist. Durch vorhandene spezifische Informationen kann die Inzidenz von mit der Narkose assoziierten Komplikationen gesenkt werden. Zur Verfügung stehendes Wissen schafft Sicherheit im Prozess der Patientenversorgung.

Die Handlungsempfehlungen von OrphanAnesthesia sind standardisiert und durchlaufen nach ihrer Erstellung einen Peer-Review-Prozess, an dem ein Anästhesist sowie ein weiterer Krankheitsexperte (z.B. Pädiater oder Neurologe) beteiligt sind. Das Projekt ist international ausgerichtet, so dass die Handlungsempfehlungen grundsätzlich in englischer Sprache veröffentlicht werden.

Ab Heft 5/2014 werden im monatlichen Rhythmus je zwei Handlungsempfehlungen als Supplement der A&I unter www.ai-online.info veröffentlicht. Als Bestandteil der A&I sind die Handlungsempfehlungen damit auch zitierfähig. Sonderdrucke können gegen Entgelt bestellt werden.

OrphanAnesthesia –

a project of the Scientific Working Group of Paediatric Anaesthesia of the German Society of Anaesthesiology and Intensive Care Medicine

The target of OrphanAnesthesia is the publication of anaesthesia recommendations for patients suffering from rare diseases in order to improve patients' safety. When it comes to the management of patients with rare diseases, there are only sparse evidence-based facts and even far less knowledge in the anaesthetic outcome. OrphanAnesthesia would like to merge this knowledge based on scientific publications and proven experience of specialists making it available for physicians worldwide free of charge.

All OrphanAnesthesia recommendations are standardized and need to pass a peer review process. They are being reviewed by at least one anaesthesiologist and another disease expert (e.g. paediatrician or neurologist) involved in the treatment of this group of patients.

The project OrphanAnesthesia is internationally oriented. Thus all recommendations will be published in English.

Starting with issue 5/2014, we'll publish the OrphanAnesthesia recommendations as a monthly supplement of A&I (Anästhesiologie & Intensivmedizin). Thus they can be accessed and downloaded via www.ai-online.info. As being part of the journal, the recommendations will be quotable. Reprints can be ordered for payment.

Bisher in A&I publizierte Handlungsempfehlungen finden Sie unter:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Find a survey of the recommendations published until now on:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Projektleitung

Prof. Dr. Tino Münster, MHBA

Chefarzt
Klinik für Anästhesie und
operative Intensivmedizin
Krankenhaus Barmherzige
Brüder Regensburg
Prüfeninger Straße 86
93049 Regensburg,
Deutschland

Tel.: 0941 369-2350

E-Mail: Tino.Muenster@barmherzige-regensburg.de

orphananesthesia

Anaesthesia recommendations for Amyotrophic lateral sclerosis

Disease name: Amyotrophic lateral sclerosis

ICD 10: G12.2

Synonyms: Charcot disease, Lou Gehrig's disease

Disease summary: Amyotrophic lateral sclerosis (ALS) is a rare progressive paralytic disorder characterised by degeneration of upper and lower motor neurons in the motor cortex, brainstem and spinal cord. ALS is the most common form of degenerative motor neuron disease [1,3,6,11]. Involvement of the upper motor neurons leads to weakness, spasticity, hyperreflexia and Babinski signs. Affection of the lower motor neurons causes weakness, muscular atrophy, fasciculations and cramps [11]. Brain stem affection can lead to bulbar symptoms. The course of the disease varies according to the region first affected and clinical manifestation. Usually respiratory failure is the ultimate cause of death [4].

The worldwide incidence is approximately 1/50,000 per year and the prevalence around 1/20,000. These numbers are relatively uniform in Western countries, although foci of higher frequency have been reported in the Western Pacific [23]. Incidence as well as prevalence increase with age [1]. The mean age of onset for sporadic ALS is late 50s, but earlier onset may occur in familial cases. There is a slight male preponderance (male-to-female ratio of around 1.5–2:1) in sporadic cases, but an equal ratio in familial cases [1,23].

About 5–10 % of ALS cases are familial (typically autosomal-dominant inheritance), whereas the remaining 90–95 % of ALS cases occur sporadically, but these are phenotypically indistinguishable [1,6]. Over 100 genetic variants have been associated with the risk for developing ALS, but the pathogenetic mechanism(s) remain unknown [1]. Interestingly, different gene mutations can lead to distinct phenotypes (e.g., similar age at onset, site of onset, disease duration), while other single gene mutations can lead to multiple phenotypes [6]. Genes influencing cytoskeletal dynamics or the protein and RNA homeostasis as well as trafficking processes play an important role in the centre of current research [1].

Environmental factors undoubtedly influence the complex pathogenesis, but this is incompletely understood. Environmental risk factors, which have been associated with ALS in varying levels of support include, for example, military service, different kinds of (head) trauma, smoking and exposure to heavy metals and pesticides [1].

There is a marked phenotypic heterogeneity between patients with respect to the onset, location and populations of involved motor neurons, resulting in diverse signs and symptoms [1,6,24]. "Classical" ALS usually begins in the limbs with focal weakness, but progresses within weeks to months to involve most muscles. Until late in the disease, neurons innervating eye muscles or the bladder are not affected [1,6]. Beside muscle weakness, muscle atrophy, fasciculations, spasticity and hyperreflexia may appear [24].

► **Citation:** Gaik C, Wiesmann T: Amyotrophic lateral sclerosis. Anästh Intensivmed 2023;64:S1–S13. DOI: 10.19224/ai2023.S001

However, one-third of patients present with bulbar symptoms, e.g., difficulties in chewing, speaking, swallowing; drooling of saliva as well as a slurred speech [1,26]. Dysphagia can result in a symptomatic aspiration of solids, liquids and later of solid food [28]. Furthermore, emotional lability due to involvement of frontopontine motor neurons may indicate pseudobulbar palsy, which is characterised by facial spasticity and a tendency to laugh or cry excessively in response to minor emotional stimuli [1].

Up to 20 % of ALS patients show progressive cognitive abnormalities marked by behavioural changes, leading to (frontotemporal) dementia [1].

Beside "classical" ALS, there are several atypical ALS forms such as cases with pure limb involvement and these may have longer survival. In these atypical ALS forms, the pathological burden is predominantly at one (upper or lower) motor neuron level. These forms include primary lateral sclerosis (PLS) or progressive muscular atrophy (PMA), in which their independency or entity as a variant of ALS is under debate [5].

The degree of involvement of the upper and the lower motor neurons, the body regions affected, the degrees of involvement of other systems (e.g., cognition, behaviour) and the progression rates vary among patients [6]. The time from the first symptom of ALS to diagnosis is approximately 12 months. The diagnosis is primarily based on clinical examination. Imaging of the head and spine, electromyography and laboratory test particularly serve to exclude structural lesions and other causes for paralysis [1]. The ALSFRS-R questionnaire can be used to evaluate the course of the disease and especially the patients' functional impairment [11].

Unfortunately, there is no causal therapy for ALS. Treatment options are usually palliative directed towards managing symptoms with temporary interventions (e.g., nasogastric feeding, surgical improvement of speech disorders, cough-assist devices, diaphragmatic pacing, ventilatory support or tracheotomy). Whether feeding via gastrostomy tube has a significant survival benefit is controversial [13,22,30]. Furthermore, pros and cons as well as consequences of a tracheostomy are part of an ethical discussion in the advanced care planning of ALS patients. Tracheostomy and ventilation may allow the patient to survive despite increasing paresis, but ALS may ultimately lead to a locked-in state with the inability to communicate. Drugs like edaravone and riluzole provide limited improvement [1].

Because no therapy offers substantial clinical benefit for ALS, the prognosis is poor [1,19]. As ALS progresses, there is further weakening of the diaphragm and respiratory muscles leading to dyspnoea, orthopnoea, hypoventilation, pneumonia and finally to death due to respiratory paralysis/failure or complications such as dysphagia or immobility within 3 to 5 years [1,11,24]. Mean life expectancy after symptom onset is about three years [11].

Medicine is in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnosis is wrong



Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net

Emergency information

	AIRWAY / ANAESTHETIC TECHNIQUE	Prepare for difficult airway due to: spasticity and cramps (mouth opening / neck and jaw mobility?), tracheal constriction / scar after tracheotomy – frequent pulmonary dysfunction with (severe) restrictive pattern – availability of suction (bulbar symptoms) – consider glycopyrrolate for premedication – consider synchronisation of respirator and diaphragmatic pacing system (if applicable) – no general (dis)advantage for GA (TIVA / balanced) or RA – peripheral / neuraxial RA should be considered as safe and feasible alternative – consider NIV during RA– anticipate increased autonomic dysfunction during neuraxial RA
B	BLOOD PRODUCTS (COAGULATION)	No specific recommendations
C	CIRCULATION	Treat hypovolaemia (malnutrition, dehydration, autonomic dysfunction) – apparent primarily after induction – consider IBP measurement
D	DRUGS	No risk for MH – use short acting agents for GA – restrictive use of opioids, NDMR and sedative agents – avoid Succinylcholine (hyperkalaemia)
E	EQUIPMENT	Anaesthetic-depth (e.g., BIS) and neuromuscular monitoring recommended – use ultrasound for vessel cannulation / RA – patient positioning with caution (spasticity, muscle weakness) – prefer upper position in PACU / IMC / ICU, anticipate respiratory complications with necessity of airway suctioning and allow disposability for patient's own i.e., ventilator- / cough-assist devices and caregiver

Typical surgery

Tracheostomy.

Suprapubic bladder catheterisation.

Laparoscopic placement of diaphragmatic pacing systems [22,34].

Gastrostomy: percutaneous endoscopic gastrostomy (PEG), percutaneous radiologic gastrostomy (PRG), per-oral image-guided gastrostomy (PIG), surgical gastrostomy

(laparotomy and laparoscopy approaches have higher complications and mortality rates and are therefore less common) [13,28,33].

Type of anaesthesia

Surgical interventions requiring (general/regional) anaesthesia may accelerate the progression of ALS – referring to this, direct influence of anaesthetic drugs, inflammation and hypoperfusion, among other things, are under discussion as causing factors. Furthermore, repeated surgery and anaesthesia in these patients may lead to a considerable increase in respiratory complications [20]. Finally, each mode of anaesthesia carries specific problems in ALS patients, which should be carefully considered in this patient population [7,27].

General anaesthesia requiring invasive ventilation might result in respiratory complications in ALS patients like the necessity of prolonged ventilation, perioperative progress of respiratory muscle weakness with respiratory failure, hypoventilation, an increased risk of aspiration due to progress of bulbar symptoms, or finally a difficult weaning process.

Using short-acting agents for general anaesthesia, if applicable without muscle relaxation, may help to avoid some of these problems [18,22,26]. Furthermore, a preferably restrictive use of opioids and sedative as well as neuromuscular blocking agents is recommended due to an assumed increased sensitivity to opioids and sedative agents.

Depending on surgery, regional/neuraxial anaesthesia should be strongly considered as safe and feasible alternatives to avoid airway manipulation, invasive ventilation, sedative drugs and muscle relaxants [17,24]. In cases of patients with preoperative existing severe respiratory weakness, the use of non-invasive ventilation techniques during regional/neuraxial anaesthesia may help to support the respiratory effort [15,26]. Furthermore, regional/neuraxial anaesthesia can prevent perioperative surgical pain and reduce the need for analgetic medication with corresponding side effects [28].

The initiation of neuraxial (especially spinal) anaesthesia might result in hypotension and bradycardia due to local sympathectomy as in other patients undergoing neuraxial blockades. This phenomenon can theoretically be exacerbated due to associated autonomic dysfunction of different degree in ALS. Therefore, striving for an optimal fluid balance before spinal anaesthesia may lessen haemodynamic deviation. Further, (non-)invasive monitoring (e.g., arterial line) and vasoactive medication should be available to monitor and treat haemodynamic abnormalities [24].

Besides, patients with pre-existing CNS disorders, including ALS patients, are supposed to be at an increased risk for an exacerbation of their preoperative neurologic symptoms (“double-crush” phenomenon), whereas patients with previous neural impairment may be prone to a secondary adversity from mechanisms which are not fully understood (e.g., needle trauma, technical difficulties, drug toxicity and the selection of certain substances such as vasopressors or lidocaine) [24,32]. Nevertheless, especially in cases in which surgery does not require deep muscle paralysis or is confined to the extremities, regional/neuraxial anaesthesia may be preferred compared to general anaesthesia to reduce the risk of respiratory complications [3,24]. Various regional/neuraxial techniques have been (solely) used successfully in the anaesthetic management of ALS patients, e.g., an open appendectomy or inguinal herniorrhaphy with an epidural anaesthesia, a radiologically inserted gastrostomy tube placement with paravertebral block, lumbar plexus and sciatic nerve blocks as well as a combined spinal-epidural (CSE) anaesthesia, a femur fracture as well as a baclofen pump replacement with transversus abdominis plane (TAP) block (even in outpatients) [3,7,8,10,17,28,31].

However, there is currently no ideal or evidence-based universal agreement on the ideal anaesthetic technique (regional/general anaesthesia) for ALS patients. The decision for general or regional anaesthesia should be individualised on a case-by-case basis, considering a thorough risk-benefit analysis, respecting the patients' wishes and striving for a perioperative multidisciplinary approach [24].

Necessary additional preoperative testing (beside standard care)

There is no general recommendation or protocol for an ideal preoperative assessment of ALS patients, but it should be based on the individual patient as well as the attending anaesthesiologist with input from the managing neurologist/other primary clinician.

Depending on further comorbidities, preoperative assessment should focus on identifying organ dysfunction, particularly with special reference to the lung. ALS patients often pass through frequent pulmonary function tests (e.g., spirometry) – the results of these tests (e.g., SNIP, FVC, FEV₁, FEV₁/FVC) should be reviewed preoperatively as a key indicator to determine whether these patients require postoperative monitoring, special support or non-invasive or even (prolonged) invasive ventilation [11,29]. It is useful if patients meet criteria for postoperative non-invasive ventilation that they are started on this therapy prior to surgery so that they can develop tolerance to the mask before needing it in the immediate postoperative period [22].

Further diagnostics (e.g., chest X-ray, ECG, echocardiography, laboratory tests, blood gas analysis) should be performed on an individual basis and depending on clinical signs.

Particular preparation for airway management

Basically, evaluation and preparation for airway management in patients with ALS should follow common practice standards for airway management.

Airway examination should be performed carefully and with particular attention to the patients' anatomic and dysmorphic features (e.g., spasticity, tracheal constriction/scar after tracheotomy) with a focus on mouth-opening, jaw mobility as well as head and neck anatomy to evaluate potential airway problems.

In tracheotomised patients, the medical history should also include relevant complications of the artificial airway (scars, difficulties in changing the tracheostomy tube, regular frequency of suctioning the airway).

Difficult airway management should be anticipated with backup strategies planned in advance. Due to frequently pulmonary dysfunction, a sufficient pre-oxygenation is essential. Bag-mask-ventilation may be difficult due to spasticity and a frequent (severe) restrictive pattern in pulmonary dysfunction. Additional devices (e.g., oral {Guedel pattern} airway, nasopharyngeal airway) and adequate personnel resources should be available.

Laryngoscopy and intubation may also be challenging. Therefore, video laryngoscopy or the use of a fibre-optic scope may be useful and necessary [11]. Further, oral/tracheal suction should be available during intubation due to dysphagia and secretion. There are reports of pre-medication with an antisialagogue (e.g., glycopyrrolate) to reduce secretion [4,34,37].

Although, most (non-tracheotomised) ALS patients get endotracheal intubation for airway protection, a laryngeal mask may be a viable option in selected patients [32].

Particular preparation for transfusion or administration of blood products

No specific recommendations are given. No typical bleeding disorders were reported for ALS patients.

Particular preparation for anticoagulation

There are no specific suggestions for ALS. With respect to frequently restricted mobility up to being bedridden, anticoagulation should be considered in individual cases corresponding to current recommendations and depending on surgery and comorbidities. Furthermore, compression stockings and (limb) physiotherapy may be indicated to prevent deep vein thrombosis.

Particular precautions for positioning, transportation and mobilisation

Many ALS patients need a different degree of help and support in their daily activity (including bedding and movement) due to physical disability/weakness. Spasticity, muscle cramps/atrophy/weakness in many ALS patients requires extremely careful positioning and mobilisation on an individual basis.

Surgery in prone position (and spinal anaesthesia) is reported without complications, but this should be considered carefully in awake ALS patients without airway protection [25]. Supine position (e.g., in the postoperative setting) may also be stressful for ALS patients, because the use of accessory muscles to support respiration may be necessary [26]. Upper/semi-sitting position may help to relieve respiration [15].

Interactions of chronic disease and anaesthesia medications

The therapeutic ALS drug riluzole decreased the MAC of isoflurane in animal experiments [36]. There are no data/reports for interactions in humans. Especially in patients with chronic riluzole treatment, we recommend the use of anaesthetic-depth monitoring (e.g., BIS monitoring) to guarantee adequate levels of anaesthesia.

Anaesthetic procedure

Preoperative evaluation: see details above.

Pre-medication: might be performed weighing the benefits and risks in individual patients – be aware of an increased sensitivity to sedative drugs and a high risk of, for example, hypoxaemia, airway obstruction or aspiration. Specifically, benzodiazepines and gabapentinoids should only be used after careful consideration of risks and benefits [5]. Glycopyrrolate is sometimes used as an antisialagogue to reduce secretion in ALS patients.

Patients positioning and monitoring: act with caution due to spasticity and muscle weakness. In case of monitored sedation without invasive ventilation, an upper position may support the patients' respiration (as far as possible depending on surgery).

Vessel cannulation: might be difficult due to cramps or spasticity. Ultrasound or vein finder might facilitate cannulation.

(Monitored) sedation: e.g., fentanyl, midazolam, ketamine, dexmedetomidine and propofol may be used. Providers should consider a potential increased sensitivity to opioids and sedative agents. Ideally, sedation allows for a purposeful feedback to tactile and verbal stimulation – the loss of airway and gastric reflexes should strictly be avoided in patients getting sedation (e.g., for regional anaesthesia) [24].

Induction of anaesthesia: should be performed with consideration of patient-specific risk factors, especially regarding respiratory impairment. Furthermore, due to dysphagia and malnutrition/dehydration, anaesthesiologists should be aware of hypovolemia. (Severe) hypotension following the induction of anaesthesia should be anticipated before induction (e.g., by clinical signs, passive leg raising, transthoracic echocardiography, haemodynamic monitoring, lactate). Involvement of autonomic nervous system (especially sympathetic disturbances) in ALS patients is under discussion and anaesthesiologists should be aware of unusual haemodynamic reaction/compensation in these patients with the risk of sudden instability [38].

Drugs: Using established drugs for induction and maintenance of anaesthesia was reported as being uneventful. Drugs and doses should be selected carefully because adverse effects may be more distinctive and the likelihood of emergency situations occurring is higher than in healthy patients [38]. Especially non-depolarising muscle relaxants (NDMR) should be used carefully and at the lowest possible doses (ideally controlled by relaxometry). Succinylcholine should be avoided whenever possible due to the risk of hyperkalaemia [24,29]. After reversal of NDMR, one should be aware of recurring or persistent muscle weakness and the necessity of controlled ventilation. However, both sugammadex and neostigmine with glycopyrrolate have been used to reverse NDMR in ALS patients [2,3,11,14,37]. Using cholinesterase inhibitors, providers should keep in mind the longer duration of most NDMR compared, for example, to neostigmine [2]. Basically, an appropriate dose of the reversal drug for the degree of muscle relaxation must be chosen. Furthermore, it is critical to monitor whether muscle relaxation is sufficiently reversed when using reversal drugs in ALS patients to avoid any residual block [4]. Weighing risks and benefits, anaesthesiologists may also consider general anaesthesia without the use of any muscle relaxants [18,22,35]. Total intravenous (TIVA) or balanced anaesthesia using volatile anaesthetics appears to be safe. However, inhaled anaesthetics are (controversially) discussed as being responsible for residual muscle relaxation (despite drug reversal and inconspicuous neuromuscular monitoring) as well as the degree of disease progress in some ALS patients. Anaesthesiologists should keep this in mind, even if it is currently unclear whether TIVA provides significant advantages compared to inhalation anaesthesia in the management of ALS patients. Providing inhalational anaesthesia, desflurane and sevoflurane should be preferred for maintenance due to their low lipid solubility allowing for rapid reversal and dose adjustment [3,29].

Regional/neuraxial/infiltration anaesthesia: When using established drugs, no complications were reported among patients who underwent regional anaesthetic techniques [11,17,25]. Ultrasound guidance may help to identify target structures, primarily in patients with, for example, spasticity, deformities and muscle atrophy. Furthermore, in case of cervical/brachial plexus blocks, ultrasound can help to reduce the risk of inadvertent co-anaesthesia of N. phrenicus or N. recurrens, for example, associated with a consequential progression of a pre-existing severe respiratory distress.

Ventilation: Ventilation should be lung-protective whenever possible. In patients with diaphragmatic pacing system, this device may be synchronised with the anaesthesia workstation ventilator to facilitate ventilation (and weaning) [22]. Preoperative consultation with the referral centre will improve the perioperative handling of these specific devices.

Particular or additional monitoring

Depending on the degree of pulmonary distress, an arterial line may be placed peri-operatively for blood gas monitoring [15]. Furthermore, the risk of sudden haemodynamic instability during anaesthesia may be increased in ALS patients due to affection of the autonomic nervous system [38].

Despite cognitive dysfunction/locked-in state in some ALS patients, bi-spectral index (BIS) monitoring is reported as useful for estimating the depth of anaesthesia concordant to healthy individuals [9].

Neuromuscular monitoring is indispensable when muscle relaxants are used as a part of general anaesthesia [3]. However, providers must consider a discrepancy between measured neuromuscular response and clinical symptoms [2,3,35]. A train-of-four stimulation (TOF) > 0.9 may not be used as the absolute criteria for safe extubation and full recovery from muscle paralysis in ALS patients [3,14].

Possible complications

Respiratory exhaustion and/or failure is the major concern in these patients (e.g., after residual muscle paralysis or mechanical ventilation). Respiratory distress may require prolonged mechanical ventilation as well as re-intubation [11,24]. Weaning is often prolonged and difficult [20].

Bulbar symptoms and primarily dysphagia increase the perioperative risk of aspiration.

Dysregulation or exacerbation of bulbar and autonomic nervous system involvement [24].

Post-operative care

Postoperative care should be tailored to the severity of the individual's disease and type of surgery and anaesthesia.

Basically, ALS patients may be more sensitive to muscle relaxants and opioids, resulting in postoperative respiratory failure, aspiration pneumonia, electrolyte abnormalities and hypovolaemia due to poor nutrition intake, exacerbation of neurologic symptoms and functional decline after surgery [24]. Therefore, a stay in intermediate or intensive care unit might be reasonable. Even if it is not mandatory, this may be useful for most ALS patients, especially if severe respiratory dysfunction pre-exists and controlled ventilation was necessary. The postoperative disposability of non-invasive ventilatory devices can help to accelerate extubation, further weaning and avoiding secondary respiratory deterioration [21]. However, weakness in the face or upper airway muscles can make it difficult or even impossible to introduce non-invasive ventilation in the first place [19].

Patients on non-invasive ventilation preoperatively should be placed back on this post-operatively and if they are routinely using cough assist/airway clearance devices should bring their own machine and resume their usual routine [22,29]. Handling of these devices may often be facilitated by having the patients' primary caregiver come to the post-anaesthesia care unit to help with the patients' machine. Communication may also be easier in the presence of a patients' caregiver using their tools like an alphabet table or a text editor supported by a photomechanically controlled keyboard linked to a computer [16,22].

No postoperative routine use of oxygen is recommended because ALS patients have an inherent instability of respiratory control and their drive for respirations when sleeping is based on oxygen saturation [22,29].

Bulbar symptoms like dysphagia or dysarthria as well as cognitive impairment may lead to malnutrition and require intravenous or tube feeding in cases of prolonged inpatient admission. Because ALS is characterised by a hypermetabolic state, resulting in a greater caloric intake, this may even lead to weight loss [28].

Postoperative analgesia is essential for sufficient breathing (free of pain). This requires consideration in ALS patients, since opioids may cause respiratory depression and insufficient analgesia also adversely impacts respiration [15]. Nonsteroidal anti-inflammatory agents can be given considering the usual contraindications.

Disease-related acute problems and effect on anaesthesia and recovery

Differential diagnosis: Peripheral neuropathy, Lyme disease, vitamin B12 deficiency, thyroid disease, metal toxicity are examples [1].

Emergency-like situations: aspiration, pneumonia, respiratory exhaustion and/or failure, hypoxaemia.

Ambulatory anaesthesia

There are no general recommendations regarding outpatient procedures due to a lack of reports in the literature. However, ambulatory anaesthesia is possible and might be performed in institutions with adequate resources and expertise. Especially minor procedures that require limited sedation can be performed safely on an ambulatory basis [11].

Nevertheless, most complications are not attributable to the particular procedure *per se*, but rather a sequela of the underlying disease. Therefore, more extensive procedures and, depending on pre-existing respiratory impairment, the intraoperative necessity of invasive ventilation and the possibility of professional homecare (e.g., monitoring, healthcare/nursing service, oxygen disposability), are issues to be observed. ALS patients usually should be admitted to a hospital [11].

Obstetrical anaesthesia

Patients with ALS are fertile. However, the onset of disease is usually in the fifth or sixth decade and therefore rarely affects fertile women. Due to this condition, data on ALS and pregnancy is scarce. The relationship between the hormonal change in pregnancy and

increased susceptibility to ALS are under discussion and it is still unclear whether pregnancy influences the course of ALS or vice versa [15,26].

Depending on the progression of the ALS disease, pregnant women may be admitted to a (monitor) ward during pregnancy. The timing and mode of delivery at least depends on the course and the progression of ALS in pregnant women. Since motor neurone diseases do not affect the motor and sensory nerves of the uterus, a vaginal delivery is basically possible (and preferred) [15,26]. Complications during pregnancy (especially progressive shortness of breath) may lead to (emergency) Caesarean section [15].

Respiration is the mostly affected component during pregnancy and respiratory deterioration must be assumed nearly independently from the delivery mode. The typical increase in cardiovascular work as well as tidal and minute ventilation in pregnancy may be affected due to weakness of diaphragmatic and costal muscles in ALS. Parturient with ALS may not be able to increase breathing appropriately to meet the oxygen demand during labour. Furthermore, in the last trimester of pregnancy, the diaphragmatic elevation leads to a decrease in in FRC. Therefore, recurrent testing of respiratory and pulmonary function is recommended. However, lower abdominal surgery like Caesarean section is associated with a lung volume loss sustaining for nearly two weeks [12,26,35].

To avoid pregnancy-associated increased risks of difficult airway management and pulmonary aspiration of gastric content, which would cause further challenges in ALS patients, neuraxial anaesthesia (epidural/spinal/CSE) are preferred over general anaesthesia for delivery in pregnant women with ALS. Furthermore, an epidural analgesia during labour will minimise maternal respiratory efforts [15]. However, neuraxial anaesthesia can affect, for example, intercostal muscles and hinder spontaneous breathing [12]. Nevertheless, the recommended mode of anaesthesia in these cases is under discussion [35]. Depending on the degree of bulbar symptoms, general anaesthesia may be the only protective procedure against aspiration. The combination of local sprayed anaesthetics on trachea and vocal cords before intubation, TIVA (propofol, remifentanyl) without using any muscle relaxants and local infiltration of the incision site (ropivacaine) is reported as successful for Caesarean section [35]. Considering succinylcholine as contraindicated in ALS and NDMR as critical for mother and neonate, this combination of short-acting agents may be an alternative strategy in these cases.

Riluzole as a proven therapy for ALS can be used during pregnancy [26].

Since motor neurone disease does not affect foetal development, neonatal outcomes are generally good [26].

Caring for pregnant women with ALS requires a multidisciplinary approach. This may include nutritionists and physiotherapy to avoid malnutrition and deep vein thrombosis as well as preservation of mobility [26]. Furthermore, obstetricians, neonatologists, anaesthesiologists, and neurologists should be part of the team.

References

1. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. *N Engl J Med* 2017;377:162–172
2. Chang YJ, Jung WS, Son WR, Jo YY. Discordance between Train-of-Four Response and Clinical Symptoms in a Patient with Amyotrophic Lateral Sclerosis. *Acta Med Okayama* 2014;68:125–127
3. Chang T, Huh J. Delayed neuromuscular recovery after use of sugamadex in a patient with amyotrophic lateral sclerosis : a case report. *Anesth Pain Intens Care* 2017;21:475–478
4. Chun HR, Chung J, Kim NS, Kim AJ, Kim S, Kang KS. Incomplete recovery from rocuronium-induced muscle relaxation in patients with amyotrophic lateral sclerosis using sugammadex. A case report. *Medicine* 2020;99:e18867
5. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin> (accessed 09.11.2021)
6. Grad LI, Rouleau GA, Ravits J, Cashman NR. Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS). *Cold Spring Harb Perspect Med* 2017;7:a024117
7. Hadaya IA, Gray AT, Braehler MR. Baclofen Pump Replacement in a Patient With End-Stage Amyotrophic Lateral Sclerosis: A Case Report Demonstrating Transversus Abdominis Plane Block as the Sole Anesthetic. *A A Pract* 2018;15:10:251–253
8. Hara K, Sakura S, Saito Y, Maeda M, Kosaka Y. Epidural Anesthesia and Pulmonary Function in a Patient with Amyotrophic Lateral Sclerosis. *Anesth Analg* 1996;83:878–879
9. Hayashi K, Araki R, Tanaka A. Electroencephalographic monitoring during sevoflurane anaesthesia in an amyotrophic lateral sclerosis patient with locked-in state. *J Clin Neurosci* 2017;43:126–128
10. Hobaika ABS, Neves BS. Combined Spinal-Epidural Block in a Patient with Amyotrophic Lateral Sclerosis. *Case Report. Rev Bras Anesthesiol* 2009;59:206–209
11. Hooper AM, Barbara DW, Watson JC, Sprung J, Weingarten TN. Amyotrophic lateral sclerosis and anesthesia: a case series review of the literature. *J Anesth* 2019;33:257–265
12. Jacka MJ, Sanderson F. Amyotrophic Lateral Sclerosis Presenting During Pregnancy. *Anesth Analg* 1998;86:542–543
13. Kak M, Issa NP, Roos RP, Sweitzer BJ, Gottlieb O, Guralnick A, et al. Gastrostomy tube placement is safe in advanced amyotrophic lateral sclerosis. *Neurol Res* 2016;39:16–22
14. Kelsaka E, Karakaya D, Zengin EC. Use of Sugamadex in a Patient with Amyotrophic Lateral Sclerosis. *Med Princip Pract* 2013;22:304–306
15. Kock-Cordeiro DBM, Brusse E, van den Biggelaar RJM, Eggink AJ, van der Marel CD. Combined spinal-epidural anesthesia with non-invasive ventilation during caesarean delivery of a woman with a recent diagnosis of amyotrophic lateral sclerosis. *Int J Obstet Anesth* 2018;36:108–110
16. Kowalik MM, Smiatacz T, Pajuro R, Skowronski R, Trocha H, Nyka W, et al. Anaesthesia for ophthalmologic surgical procedures in a patient with advanced amyotrophic lateral sclerosis: a case report. *Cases J* 2008;1:338
17. Kusakai M, Sawada A, Kii N, Tokinaga Y, Hirata N, Yamakage M. Epidural anesthesia combined with sedation with dexmedetomidine for appendectomy in a patient with amyotrophic lateral sclerosis: a case report. *JA Clin Rep* 2018;4:82
18. Lee D, Lee KC, Kim JY, Park YS, Chang YJ. Total intravenous anesthesia without muscle relaxant in a patient with amyotrophic lateral sclerosis. *J Anesth* 2008;22:443–445
19. Magelssen M, Holmøy T, Horn MA, Fondenæs OA, Dybwik K, Førde R. Ethical challenges in tracheostomy-assisted ventilation in amyotrophic lateral sclerosis. *J Neurol* 2018;265:2730–2736
20. Moser B, Lirk P, Lechner M, Gottardis M. General anesthesia in a patient with motor neuron disease. *Eur J Anaesth* 2004;21:921–922
21. Olivieri C, Castioni CA, Livigni S, Bersano E, Cantello R, Della Corte F, et al. Non-invasive ventilation after surgery in amyotrophic lateral sclerosis. *Acta Neurol Scand* 2014;129:e16–e19
22. Onders RP, Carlin AM, Elmo M, Sivashankaran S, Katiği B, Schilz R. Amyotrophic lateral sclerosis: the Midwestern surgical experience with the diaphragm pacing stimulation system shows that general anesthesia can be safely performed. *Am J Surg* 2009;197:386–390
23. Orphanet ([https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=106&Disease_Disease_Search_diseaseGroup=Amyotrophe-Lateralsklerose&Disease_Disease_Search_diseaseType=Pat&Krankheite\(n\)/Krankheitsgruppe=Amyotrophe-Lateralsklerose](https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=106&Disease_Disease_Search_diseaseGroup=Amyotrophe-Lateralsklerose&Disease_Disease_Search_diseaseType=Pat&Krankheite(n)/Krankheitsgruppe=Amyotrophe-Lateralsklerose))

- &title=Amyotrophe%20Lateralsklerose&search=Disease_Search_Simple; (accessed on: 09.11.2021)
24. Panchamia JK, Gurrieri C, Amundson AW. Spinal Anesthesia for Amyotrophic Lateral Sclerosis Patient Undergoing Lower Extremity Orthopedic Surgery: An Overview of the Anesthetic Considerations. *Int Med Case Rep J* 2020;13:249–254
 25. Park K, Son B, Hwang D, Jeon Y. Spinal anesthetic management for discectomy in a patient with amyotrophic lateral sclerosis. *Korean J Anesth* 2012;63:547–549
 26. Pathiraja PDM, Ranaraja SK. A Successful Pregnancy with Amyotrophic Lateral Sclerosis. *Case Rep Obstet Gynecol* 2020;2020:1247178
 27. Pinto S, Swash M, de Carvalho M. Does surgery accelerate progression of amyotrophic lateral sclerosis? *J Neurol Neurosurg Psychiatr* 2014;85:643–646
 28. Porter SB, McClain RL, Robards CB, Paz-Fumagalli R, Clendenen SR, Logvinov II, et al. Paravertebral block for radiologically inserted gastrostomy tube placement in amyotrophic lateral sclerosis. *Muscle Nerve* 2020;62:70–75
 29. Prabhakar A, Owen CP, Kaye AD. Anesthetic management of the patient with amyotrophic lateral sclerosis. *J Anesth* 2013;27:909–918
 30. Saigusa H, Yamaguchi S, Nakamura T, Komachi T, Kadosono O, Ito H, et al. Surgical Improvement of Speech Disorders Caused by Amyotrophic Lateral Sclerosis. *Tohoku J Exper Med* 2012;228:371–376
 31. Sertoz N, Karaman S. Peripheral nerve block in a patient with amyotrophic lateral sclerosis. *J Anesthesiol* 2012;26:314–315
 32. Thampi SM, David D, Chandy TT, Nadharkumar A. Anesthetic management of a patient with amyotrophic lateral sclerosis for transurethral resection of bladder tumor. *Ind J Anaesth* 2013;57:197–199
 33. Thomas K, Schrager J, Neel R, Brook L. Percutaneous endoscopic gastrostomy tube placement in amyotrophic lateral sclerosis: a case series with a multidisciplinary, team-based approach. *Ann Gastroenterol* 2020;33:480–484
 34. Trivedi S, Tibrewala N, Balsara KP. Anaesthetic management of a patient with amyotrophic lateral sclerosis undergoing laparoscopic diaphragmatic pacing. *Ind J Anaesth* 2015;59:683–685
 35. Xiao W, Zhao L, Wang F, Sun H, Wang T, Zhao G. Total intravenous anesthesia without muscle relaxant in a parturient with amyotrophic lateral sclerosis undergoing cesarean section: a case report. *J Clin Anesth* 2017;36:107–109
 36. Xing Y, Zhang Y, Stabernack CR, Eger EI, Gray AT. The use of the potassium channel activator riluzole to test whether potassium channels mediate the capacity of isoflurane to produce immobility. *Anesth Analg* 2003;97:1020–1024
 37. Yoo JH, Kim SI, Park SY, Jun MR, Kim YE, Kim HJ. Use of sugammadex in a patient with progressive muscular atrophy and in a patient with amyotrophic lateral sclerosis. *Case report. Medicine* 2017;96:23(e7098)
 38. You TM, Kim S. Pulseless electrical activity during general anesthesia induction in patients with amyotrophic lateral sclerosis. *J Dent Anesth Pain Med* 2017;17:235–240.

Date last modified: **November 2021**

Authors:

Christine Gaik, Anaesthesiologist, University Clinic Marburg, Germany
gaikc@med.uni-marburg.de

Thomas Wiesmann, Anaesthesiologist, Diakonie-Clinic Schwaebisch Hall, Germany
thomas.wiesmann@diakoneo.de

Disclosure The authors have no financial or other competing interest to disclose. This recommendation was unfunded.

Reviewers:

Toby Weingarten, Anaesthesiologist, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA
weingarten.toby@mayo.edu

David Czell, Neurologist, Rapperswil, Switzerland
david.czell@hin.ch

Disclosure The reviewers have no financial or other competing interest to disclose.

Herausgeber



DGAI

Deutsche Gesellschaft
für Anästhesiologie und
Intensivmedizin e.V.
Präsident: Prof. Dr.
B. Pannen, Düsseldorf



BDA

Berufsverband Deutscher
Anästhesisten e.V.
Präsident: Prof. Dr.
G. Geldner, Ludwigsburg †

Schriftleitung

Präsident/in der Herausgeberverbände
Gesamtschriftleiter/Editor-in-Chief:
Prof. Dr. Dr. Kai Zacharowski,
ML FRCA FESAIC, Frankfurt
Stellvertretender Gesamtschriftleiter/
Deputy Editor:
Prof. Dr. T. Volk, Homburg/Saar
CME-Schriftleiter/CME-Editor:
Prof. Dr. W. Zink, Ludwigshafen

Redaktionskomitee/Editorial Board

Prof. Dr. G. Beck, Wiesbaden
Prof. Dr. A. Brinkmann, Heidenheim
Prof. Dr. H. Bürkle, Freiburg
Prof. Dr. B. Ellger, Dortmund
Prof. Dr. K. Engelhard, Mainz
Prof. Dr. M. Fischer, Göppingen
Prof. Dr. U. X. Kaisers, Ulm
Prof. Dr. T. Loop, Freiburg
Prof. Dr. W. Meißner, Jena
Prof. Dr. C. Nau, Lübeck
RAin A. Pfundstein, Nürnberg
Dr. M. Rähmer, Mainz
Prof. Dr. A. Schleppers, Nürnberg
Prof. Dr. M. Thiel, Mannheim
Prof. Dr. F. Wappler, Köln
Prof. Dr. M. Weigand, Heidelberg

Redaktion/Editorial Staff

Carolin Sofia Kopp B.A.
Korrespondenzadresse:
Neuwieder Straße 9 | 90411 Nürnberg |
Deutschland | Tel.: 0911 9337812
E-Mail: anaesth.intensivmed@dgai-ev.de

Verlag & Druckerei

Aktiv Druck & Verlag GmbH

An der Lohwiese 36 |
97500 Ebelsbach | Deutschland
www.aktiv-druck.de



Geschäftsführung

Wolfgang Schröder | Jan Schröder |
Nadja Schwarz
Tel.: 09522 943560 | Fax: 09522 943567
E-Mail: info@aktiv-druck.de

Anzeigen | Vertrieb

Pia Müller | Robert Kux
Tel.: 09522 943570 | Fax: 09522 943577
E-Mail: anzeigen@aktiv-druck.de

Verlagsrepräsentanz

Jürgen Distler
Neuwieder Straße 9 | 90411 Nürnberg
Tel.: 0171 9432534
E-Mail: jdistler@bda-ev.de

Herstellung | Gestaltung

Pia Müller | Robert Kux |
Stefanie Triebert
Tel.: 09522 943570 | Fax: 09522 943577
E-Mail: ai@aktiv-druck.de

Titelbild

Gestaltung: Klaus Steigner
Paumgartnerstraße 28 | 90429 Nürnberg
E-Mail: mazyblue@klaus-steigner.de
www.klaus-steigner.de

Erscheinungsweise 2023

Der 64. Jahrgang erscheint jeweils zum
Monatsanfang, Heft 7/8 als Doppelausgabe.

Bezugspreise (inkl. Versandkosten):

• Einzelhefte	30,- €
• Jahresabonnement:	
Europa (ohne Schweiz)	258,- €
(inkl. 7 % MwSt.)	
Schweiz	266,- €
Rest der Welt	241,- €

Mitarbeiter aus Pflege, Labor, Studenten und Auszubildende (bei Vorlage eines entsprechenden Nachweises)

Europa (ohne Schweiz)	94,- €
(inkl. 7 % MwSt.)	
Schweiz	90,- €
Rest der Welt	94,- €

**Für Mitglieder der DGAI und/oder
des BDA ist der Bezug der Zeitschrift
im Mitgliedsbeitrag enthalten.**

Allgemeine Geschäfts- und Liefer- bedingungen

Die allgemeinen Geschäfts- und Liefer-
bedingungen entnehmen Sie bitte dem
Impressum auf www.ai-online.info

Indexed in **Current Contents®/Clinical
Medicine, EMBASE/Excerpta Medica;
Medical Documentation Service;
Research Alert; Sci Search; SUBIS
Current Awareness in Biomedicine;
VINITI: Russian Academy of Science.**

Nachdruck | Urheberrecht

Die veröffentlichten Beiträge sind urhe-
berrechtlich geschützt. Jegliche Art von
Vervielfältigungen – sei es auf mechani-
chem, digitalem oder sonst möglichem
Wege – bleibt vorbehalten. Die Aktiv
Druck & Verlags GmbH ist allein auto-
risiert, Rechte zu vergeben und Sonder-
drucke für gewerbliche Zwecke, gleich
in welcher Sprache, herzustellen. An-
fragen hierzu sind nur an den Verlag zu
richten. Jede im Bereich eines gewerbli-
chen Unternehmens zulässig hergestellte
oder benutzte Kopie dient gewerblichen
Zwecken gem. § 54 (2) UrhG. Die Wie-
dergabe von Gebrauchsnamen, Handels-
namen, Warenbezeichnungen usw. in
dieser Zeitschrift berechtigt auch ohne
besondere Kennzeichnung nicht zu der
Annahme, dass solche Namen im Sinne
der Warenzeichen- und Markenschutz-
Gesetzgebung als frei zu betrachten wä-
ren und daher von jedermann benutzt
werden dürften.

Wichtiger Hinweis

Für Angaben über Dosierungsanwei-
sungen und Applikationsformen kann
vom Verlag und den Herausgebern keine
Gewähr übernommen werden. Derartige
Angaben müssen vom jeweiligen An-
wender im Einzelfall anhand anderer
Literaturstellen auf ihre Richtigkeit über-
prüft werden. Gleiches gilt für berufs-
und verbandspolitische Stellungnahmen
und Empfehlungen.

Allein aus Gründen der besseren Les-
barkeit wird auf die gleichzeitige Ver-
wendung männlicher, weiblicher und
weiterer Sprachformen verzichtet. Sämt-
liche Personenbezeichnungen gelten für
alle Geschlechterformen. Dies impliziert
keinesfalls eine Benachteiligung der je-
weils anderen Geschlechter, sondern ist
als geschlechtsneutral zu verstehen.

Die Beiträge aus der A&I
finden Sie online unter:
www.ai-online.info

CONTACT US

Please do not hesitate to contact us. We will be glad to answer and provide further information to you at any time.

.....
Name

.....
First Name

.....
Department / Hospital

.....
Place

.....
Telephone

.....
E-Mail

.....
Date / Signature

Please contact me for further information

☐

I would like to participate in the project

☐

ADDRESS

German Society of Anaesthesiology and
Intensive Care Medicine
Ursula Homberg
Neuwieder Straße 9 | 90411 Nuremberg | Germany
Tel.: +49-911-9337828
Email: uhomberg@orphananesthesia.eu